Phenotypic and cytogenetic features
| . | Cyclin D1-positive . | Cyclin D1-negative . | P . |
|---|---|---|---|
| Immunophenotype | |||
| CD5 | 103/109 (94%) | 20/20 (100%) | .36 |
| CD20 | 101/101 (100%) | 17/17 (100%) | 1.00 |
| CD23 | 10/88 (11%) | 4/15 (27%) | .12 |
| κ:λ | 44:55 | 7:10 | .91 |
| Flow cytometry | |||
| CD20 bright:dim | 39:1 | 5:2 | .06 |
| IgL bright:dim | 36:3 | 6:1 | .50 |
| Cytogenetics | |||
| t(11;14)(q13;q32)+ | 184-150 | 0 | .09 |
| t(11;14)(q13;q32)− | 18 | 3 | |
| No metaphase | 12 | 2 | |
| Not examined | 80 | 13 |
| . | Cyclin D1-positive . | Cyclin D1-negative . | P . |
|---|---|---|---|
| Immunophenotype | |||
| CD5 | 103/109 (94%) | 20/20 (100%) | .36 |
| CD20 | 101/101 (100%) | 17/17 (100%) | 1.00 |
| CD23 | 10/88 (11%) | 4/15 (27%) | .12 |
| κ:λ | 44:55 | 7:10 | .91 |
| Flow cytometry | |||
| CD20 bright:dim | 39:1 | 5:2 | .06 |
| IgL bright:dim | 36:3 | 6:1 | .50 |
| Cytogenetics | |||
| t(11;14)(q13;q32)+ | 184-150 | 0 | .09 |
| t(11;14)(q13;q32)− | 18 | 3 | |
| No metaphase | 12 | 2 | |
| Not examined | 80 | 13 |
Including 1 patient with t(11;22)(q13;q11).
IgL, immunoglobulin light chain.